WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world’s leading pharmaceutical and biotechnology companies today announced the signing of multiple new contracts with an aggregate value of approximately $1.7 million. These contracts, which are with a leading international biotechnology company, are for regulatory submission services, support of new clinical trials, and changes-of-scope for existing studies. The therapeutic areas covered in these contracts are oncology and rheumatology. Revenue recognition began during the fourth quarter of 2007 and continues on a proportional performance basis over the life of the contract as services are performed.
